Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Michael David Chuong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8328-7518; OpenAlex author ID A5012399386. Sources: ClinicalTrials.gov.

Their work

Papers
27 (first author 1, last author 7)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
86
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 trial · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 4 papers · 2024: 2 papers · 2025: 5 papers · 2026: 4 papers

Papers 27

  1. Innovative Targets, New Technologies, Same Tenacity: Radiation Therapy's Evolving Role in Pancreatic Cancer. Last author DOI 10.1016/j.ijrobp.2025.11.058↗
  2. Patterns of Failure After Definitive Ablative 5-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ijrobp.2026.03.048↗
  3. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2026.07.002↗
  4. Rethinking Radiation Therapy in the Era of RAS Inhibition for Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyag433↗
  5. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  6. The Role of MR Guided Radiation Therapy in Pancreatic Cancer Treatment. Co-author DOI 10.1016/j.semradonc.2025.08.002↗
  7. First Spanish Experience with Stereotactic MR-Guided Adaptive Radiotherapy (SMART) in Borderline Resectable and Locally Advanced Pancreatic Cancer: A Prospecti… Co-author DOI 10.3390/biomedicines13102390↗
  8. Ablative Five-Fraction CT Versus MR-Guided Stereotactic Body Radiation Therapy for Pancreatic Cancer: In Silico Evaluation of Interfraction Anatomic Changes as… Last author DOI 10.3390/cancers17132061↗
  9. Multi-Institutional Comparison of Ablative 5-Fraction Magnetic Resonance-Guided Online Adaptive Versus 15/25-Fraction Computed Tomography-Guided Moderately Hyp… Co-author DOI 10.3390/cancers17152596↗
  10. SBRT for Pancreatic Cancer: A Radiosurgery Society Case-Based Practical Guidelines to Challenging Cases. Last author DOI 10.1016/j.prro.2024.06.004↗
  11. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label… Co-author DOI 10.1016/j.radonc.2023.110064↗
  12. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable… Last author DOI 10.1016/j.ijrobp.2023.05.023↗
  13. Online adaptive radiotherapy: Assessment of planning technique and its impact on longitudinal plan quality robustness in pancreatic cancer. Last author DOI 10.1016/j.radonc.2023.109869↗
  14. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic R… Last author DOI 10.1177/10732748221150228↗
  15. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1177/10732748231219069↗
  16. Elective Target Coverage for Pancreatic Cancer: When Less Does Not Clearly Achieve More. Co-author DOI 10.1016/j.ijrobp.2021.08.024↗
  17. Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report. First author DOI 10.1016/j.meddos.2021.04.006↗
  18. Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Co-author DOI 10.3389/fonc.2021.628155↗
  19. Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer. Co-author DOI 10.21037/jgo.2018.03.14↗
  20. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Co-author DOI 10.1016/j.soc.2017.01.012↗
  21. Does lymphocyte-to-monocyte ratio before, during, or after definitive chemoradiation for locally advanced pancreatic cancer predict for clinical outcomes? Last author DOI 10.21037/jgo.2017.06.14↗
  22. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy co… Co-author DOI 10.21037/jgo.2016.03.15↗
  23. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. Co-author DOI 10.3978/j.issn.2078-6891.2015.075↗
  24. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarc… Co-author DOI 10.3109/0284186x.2015.1004367↗
  25. Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us? Co-author DOI 10.3978/j.issn.2078-6891.2014.025↗
  26. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Co-author DOI 10.1016/j.ijrobp.2013.02.022↗
  27. Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. Co-author PMID 22368736↗

Trials 1

  1. Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer Principal investigator NCT03621644↗

Closest collaborators

The 25 strongest of 86 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kathryn Elizabeth Mittauer · 7 shared papers, 2021–2026 · strength 1.21
  2. Adeel Kaiser · 5 shared papers, 2017–2026 · strength 0.88
  3. Eileen Mary O'Reilly · 2 shared papers, 2025–2026 · strength 0.83
  4. Hyun Jee Kim · 4 shared papers, 2023–2025 · strength 0.82
  5. Michael Frederick Bassetti · 5 shared papers, 2021–2026 · strength 0.78
  6. Percy P. Lee · 4 shared papers, 1 shared trial, 2019–2024 · strength 0.76
  7. Sarah E. Hoffe · 8 shared papers, 2011–2024 · strength 0.72
  8. Jessica M. Frakes · 6 shared papers, 2015–2026 · strength 0.70
  9. Nina Niu Sanford · 3 shared papers, 2022–2026 · strength 0.67
  10. Marsha Reyngold · 3 shared papers, 2025–2026 · strength 0.61
  11. Karyn A. Goodman · 3 shared papers, 2024–2026 · strength 0.59
  12. Amol Kumar Narang · 3 shared papers, 2024–2026 · strength 0.59
  13. Luca Boldrini · 3 shared papers, 2023–2026 · strength 0.59
  14. Parag Jitendra Parikh · 3 shared papers, 1 shared trial, 2019–2024 · strength 0.58
  15. Krishan R. Jethwa · 2 shared papers, 2026 · strength 0.54
  16. Christopher H. Crane · 3 shared papers, 2021–2025 · strength 0.48
  17. Daniel A. Low · 2 shared papers, 1 shared trial, 2019–2024 · strength 0.48
  18. William Adrian Hall · 3 shared papers, 2021–2025 · strength 0.47
  19. John Michael Bryant · 3 shared papers, 2021–2023 · strength 0.44
  20. Daniel Tandel Chang · 2 shared papers, 2024–2026 · strength 0.40
  21. Mokenge Peter Malafa · 6 shared papers, 2011–2023 · strength 0.37
  22. Pamela Joy Hodul · 6 shared papers, 2011–2023 · strength 0.37
  23. Alden D'Souza · 1 shared paper, 2025 · strength 0.37
  24. Eric David Miller · 1 shared paper, 2026 · strength 0.32
  25. William F. Regine · 4 shared papers, 2014–2018 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.